Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022;8:420–44.

Article  PubMed  Google Scholar 

Coombes M, Briggs K, Bone J, Clayman G, El-Naggar A, Dent S. Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation. Oncogene. 2003;22:8902–11.

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, et al. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Cancer Netw 2020;18:1160–70.

Article  Google Scholar 

Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1432–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim IH, Lee HJ. The frontline immunotherapy-based treatment of advanced clear cell renal cell carcinoma: current evidence and clinical perspective. Biomedicines. 2022;10:251.

Diaz-Montero CM, Rini BI, Finke JH. The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020;16:721–35.

Article  PubMed  Google Scholar 

Zhu G, Pei L, Yin H, Lin F, Li X, Zhu X, et al. Profiles of tumor-infiltrating immune cells in renal cell carcinoma and their clinical implications. Oncol Lett. 2019;18:5235–42.

CAS  PubMed  PubMed Central  Google Scholar 

Heidegger I, Pircher A, Pichler R. Targeting the tumor microenvironment in renal cell cancer biology and therapy. Front Oncol 2019;9:490.

Article  PubMed  PubMed Central  Google Scholar 

Lui PP, Cho I, Ali N. Tissue regulatory T cells. Immunology. 2020;161:4–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao H, Liao X, Kang Y. Tregs: Where we are and what comes next? Front Immunol. 2017;8:1578.

Article  PubMed  PubMed Central  Google Scholar 

Allos H, Al Dulaijan BS, Choi J, Azzi J. Regulatory T cells for more targeted immunosuppressive therapies. Clin Lab Med. 2019;39:1–13.

Article  PubMed  Google Scholar 

Wing JB, Tanaka A, Sakaguchi S. Human FOXP3. Immunity. 2019;50:302–16.

Article  CAS  PubMed  Google Scholar 

Kressler C, Gasparoni G, Nordström K, Hamo D, Salhab A, Dimitropoulos C, et al. Targeted de-methylation of the FOXP3-TSDR is sufficient to induce physiological FOXP3 expression but not a functional Treg Phenotype. Front Immunol. 2020;11:609891.

Article  CAS  PubMed  Google Scholar 

Khosravi M, Bidmeshkipour A, Cohen JL, Moravej A, Hojjat-Assari S, Naserian S, et al. Induction of CD4(+)CD25(+)FOXP3(+) regulatory T cells by mesenchymal stem cells is associated with modulation of ubiquitination factors and TSDR demethylation. Stem Cell Res Ther 2018;9:273.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother. 2007;56:1743–53.

Article  PubMed  PubMed Central  Google Scholar 

Liotta F, Gacci M, Frosali F, Querci V, Vittori G, Lapini A, et al. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int. 2011;107:1500–6.

Article  CAS  PubMed  Google Scholar 

Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14:6674–82.

Article  CAS  Google Scholar 

Pan Q, Wang L, Chai S, Zhang H, Li B. The immune infiltration in clear cell Renal Cell Carcinoma and their clinical implications: A study based on TCGA and GEO databases. J Cancer. 2020;11:3207–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pompura, SL & Dominguez-Villar, M The PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function. J Leukoc Biol (2018) https://doi.org/10.1002/JLB.2MIR0817-349R.

Delgoffe GM, Woo SR, Turnis ME, Gravano DM, Guy C, Overacre AE, et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature. 2013;501:252–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan M, Jene N, Byrne D, Millar EK, O’Toole SA, McNeil CM, et al. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res. 2011;13:R47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mezzapelle R, Leo M, Caprioglio F, Colley LS, Lamarca A, Sabatino L, et al. CXCR4/CXCL12 Activities in the tumor microenvironment and implications for tumor immunotherapy. Cancers. 2022;14:2314.

Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 2011;71:5522–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li B, Zeng Y, Reeves PM, Ran C, Liu Q, Qu X, et al. AMD3100 augments the efficacy of Mesothelin-targeted, immune-activating VIC-008 in Mesothelioma by modulating intratumoral immunosuppression. Cancer Immunol Res. 2018;6:539–51.

Article  CAS  PubMed  Google Scholar 

Chen IX, Chauhan VP, Posada J, Ng MR, Wu MW, Adstamongkonkul P, et al. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc Natl Acad Sci USA. 2019;116:4558–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zeng Y, Li B, Liang Y, Reeves PM, Qu X, Ran C, et al. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. FASEB J. 2019;33:6596–608.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Portella L, Vitale R, De Luca S, D’Alterio C, Ieranò C, Napolitano M, et al. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS One. 2013;8:e74548.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Maro S, Trotta AM, Brancaccio D, Di Leva FS, La Pietra V, Ieranò C, et al. Exploring the N-terminal region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-stable cyclic peptides as novel, potent C-X-C Chemokine Receptor Type 4 (CXCR4) antagonists. J Med Chem. 2016;59:8369–80.

Article  PubMed  Google Scholar 

Di Maro S, Di Leva FS, Trotta AM, Brancaccio D, Portella L, Aurilio M, et al. Structure-activity relationships and biological characterization of a novel, potent, and serum stable C-X-C Chemokine receptor Type 4 (CXCR4) antagonist. J Med Chem. 2017;60:9641–52.

Article  PubMed  Google Scholar 

Santagata S, Napolitano M, D’Alterio C, Desicato S, Maro SD, Marinelli L, et al. Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. Oncotarget. 2017;8:77110–20.

Article  PubMed  PubMed Central  Google Scholar 

Santagata S, Rea G, Castaldo D, Napolitano M, Capiluongo A, D’Alterio C, et al. Hepatocellular carcinoma (HCC) tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) tumor microenvironment. Hepatol Int (2023). https://doi.org/10.1007/s12072-023-10537-6.

Fritzsching B, Haas J, König F, Kunz P, Fritzsching E, Pöschl J, et al. Intracerebral human regulatory T cells: analysis of CD4+ CD25+ FOXP3+ T cells in brain lesions and cerebrospinal fluid of multiple sclerosis patients. PLoS One. 2011;6:e17988.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haas J, Schopp L, Storch-Hagenlocher B, Fritzsching B, Jacobi C, Milkova L, et al. Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis. Blood. 2008;111:761–6.

Article  CAS  PubMed  Google Scholar 

Durr C, Pfeifer D, Claus R, Schmitt-Graeff A, Gerlach UV, Graeser R, et al. CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. Cancer Res. 2010;70:10170–81.

Article  PubMed  Google Scholar 

Liu HR, Li WM. Treg-specific demethylated region activity in isolated regulatory t lymphocytes is a surrogate for disease severity in hepatocellular carcinoma. IUBMB life. 2015;67:355–60.

Article  CAS  PubMed  Google Scholar 

Rainbow DB, Yang X, Burren O, Pekalski ML, Smyth DJ, Klarqvist MD, et al. Epigenetic analysis of regulatory T cells using multiplex bisulfite sequencing. Eur J Immunol. 2015;45:3200–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wegrzyn AS, Kedzierska AE, Obojski A. Identification and classification of distinct surface markers of T regulatory cells. Front Immunol. 2022;13:1055805.

Article  CAS  PubMed  Google Scholar 

Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, et al. Interferon-γ drives T. Cell. 2017;169:1130–1141.e1111.

Article  CAS  PubMed